The company will have the opportunity to illustrate its concepts and progress to thought leaders in the investment and healthcare community.
Rainer Henning, CEO of Biomay commented: "We are proud to be invited as only one of four privately held companies and one of very few Europeans to present at this premier healthcare event. It adds credibility to our strife for the development of novel treatment options for allergy sufferers."
About Biomay
Biomay AG is a privately held biopharmaceutical company based in Vienna, Austria. The company is committed to be a leader in the discovery and development of innovative allergy therapeutics. Besides BM32, the company has a pipeline of products for the treatment of other major allergies caused by airborne allergens. www.biomay.com
Biomay to present at the Rodman & Renshaw 14th Annual Global Healthcare Conference
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.